Associated tags: HER2, Engineering, Patient, Conjugation, Drug development, Zymeworks, Biotechnology, Health, Pharmaceutical, Research, Pharmaceutical industry, Inc., Clinical Trials, Oncology, NYSE
Locations: UK, SPAIN, AUSTRALIA, WASHINGTON, NEW ZEALAND, JAPAN, CANADA, DELAWARE, IRELAND, KM, LATIN AMERICA, BRAZIL, BOSTON, BALTIMORE, MIDDLETOWN, DE, US, BRITISH COLUMBIA, NY, NEW YORK, FL, UNITED STATES
Retrieved on:
Thursday, February 3, 2022
Oncology,
Health,
Clinical Trials,
General Health,
Pharmaceutical,
Biotechnology,
Drug development,
Engineering,
Inc.,
Patient,
Twitter,
HER2,
NYSE,
Zymeworks,
Conference,
Conjugation,
Fine chemical Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will participate in upcoming investor conferences.
Key Points:
- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will participate in upcoming investor conferences.
- Zymeworks will participate virtually in one-on-one meetings and a fireside chat on February 9th at 1:00 p.m.
- Zymeworks will participate virtually in one-on-one meetings and a fireside chat on February 17th at 3:40 p.m.
- Zymeworks suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates.
Retrieved on:
Wednesday, January 19, 2022
Oncology,
Health,
Clinical Trials,
General Health,
Pharmaceutical,
Biotechnology,
People,
Forward-looking statement,
Patient,
ACE2,
CD47,
Cholangiocarcinoma,
HER2,
Conjugation,
Biotechnology,
MET,
BTC,
COVID-19,
Board of directors,
Inc.,
Severe acute respiratory syndrome coronavirus 2,
CMO,
COO,
NYSE,
Safety,
ESMO,
Completeness,
Intellectual property,
IND,
Â,
Review,
Leadership,
VP,
Time,
Private Securities Litigation Reform Act,
Research and development,
Company,
United,
Drug development,
Q4,
Workforce,
Twitter,
GEA,
Engineering,
Chair,
Partnership,
Board,
Investment,
Fine chemical,
Management,
Renewable energy,
Medical imaging,
Medicine,
Pharmaceutical industry,
Bank,
Research,
Pfizer,
BeiGene,
Zymeworks Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today provided a corporate update on its key strategic priorities for 2022 and 2023 in addition to confirming its upcoming clinical development milestones for zanidatamab and ZW49.
Key Points:
- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today provided a corporate update on its key strategic priorities for 2022 and 2023 in addition to confirming its upcoming clinical development milestones for zanidatamab and ZW49.
- These measures, including the reduction in our workforce announced today, provide opportunities to reduce our future planned expenditures while continuing to fund our key priorities for 2022 and 2023.
- The Company intends to report full Q4 and FY 2021 results and provide any further corporate updates on February 24, 2022.
- Zymeworks suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates.
Retrieved on:
Saturday, January 15, 2022
Oncology,
Health,
General Health,
Research,
Science,
Pharmaceutical,
Biotechnology,
Disability,
Patient,
HER2,
Conjugation,
Inc.,
NYSE,
Option,
Death,
Zymeworks,
Drug development,
Employment,
Twitter,
Engineering,
Security (finance),
Fine chemical Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported, as required by the New York Stock Exchange Listed Company Manual Rule 303A.08 (the NYSE Rule), an equity inducement award to Mr. Kenneth Galbraith, Zymeworks new Chair, President and Chief Executive Officer.
Key Points:
- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported, as required by the New York Stock Exchange Listed Company Manual Rule 303A.08 (the NYSE Rule), an equity inducement award to Mr. Kenneth Galbraith, Zymeworks new Chair, President and Chief Executive Officer.
- In accordance with the NYSE Rule, Zymeworks approved the grant of the following equity award to Mr. Galbraith as a material inducement to Mr. Galbraith entering into employment with Zymeworks: effective as of the date his employment with Zymeworks began, a stock option to purchase 500,000 of the companys common shares (the Options).
- Mr. Galbraiths employment with the company began on January 15, 2022 (the Start Date).
- Zymeworks suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates.
Retrieved on:
Thursday, January 6, 2022
Research,
Clinical Trials,
Biotechnology,
Health,
Pharmaceutical,
General Health,
Other Science,
Science,
Oncology,
Conjugation,
Patient,
NYSE,
Engineering,
Drug development,
HER2,
Inc.,
Conference,
Twitter,
Fine chemical Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that Neil Klompas, Zymeworks Chief Operating Officer and Chief Financial Officer, will present at the upcoming 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022 at 9:45 a.m.
Key Points:
- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that Neil Klompas, Zymeworks Chief Operating Officer and Chief Financial Officer, will present at the upcoming 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022 at 9:45 a.m.
- The presentation will be webcast live and available for replay on Zymeworks website at http://ir.zymeworks.com/events-and-presentations .
- Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics.
- Zymeworks suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates.
Retrieved on:
Wednesday, January 5, 2022
Biotechnology,
Health,
Pharmaceutical,
Clinical Trials,
Oncology,
Conjugation,
Engineering,
Safety,
COVID-19,
University,
Growth,
Research,
Company,
Forward-looking statement,
Patient,
NYSE,
Cancer,
Inc.,
Twitter,
LSE,
CEO,
Chairperson,
Commerce,
HER2,
Private Securities Litigation Reform Act,
QLT,
Board of directors,
Drug development,
CFO,
Multimedia,
COO,
Investment,
Biotechnology,
Leadership,
Fine chemical,
Pharmaceutical industry,
Angiotech Pharmaceuticals,
Zymeworks Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the appointment of Mr. Kenneth Galbraith as Chair and Chief Executive Officer (CEO) of Zymeworks, effective on or before February 1, 2022.
Key Points:
- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the appointment of Mr. Kenneth Galbraith as Chair and Chief Executive Officer (CEO) of Zymeworks, effective on or before February 1, 2022.
- Mr. Galbraith will succeed Zymeworks co-founder Ali Tehrani, Ph.D., who has served as President and CEO since 2003.
- Dr. Tehrani will remain as an advisor to the Company to assist with the transition.
- Zymeworks suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates.
Retrieved on:
Thursday, December 9, 2021
Biotechnology,
Pharmaceutical,
Health,
Clinical Trials,
Accelerated approval (FDA),
Engineering,
NYSE,
Twitter,
Trastuzumab,
Forward-looking statement,
Research,
Inc.,
White Light Rock & Roll Review,
Phagocytosis,
Biliary tract,
CAPOX,
Safety,
Progression-free survival,
Drug development,
PD-1,
Private Securities Litigation Reform Act,
Compte rendu,
Patient,
Breakthrough therapy,
Priority review,
FP,
Zymeworks,
Epitope,
RECIST,
BeiGene,
European Medicines Agency,
Breast,
FDA,
HER2,
Orphan drug,
Conjugation,
Tislelizumab,
Pharmaceutical industry,
the HERIZON-GEA-01 Clinical Trial,
the Zymeworks-BeiGene Collaboration,
Zanidatamab,
Zymeworks Inc.,
THE HERIZON-GEA-01 CLINICAL TRIAL,
THE ZYMEWORKS-BEIGENE COLLABORATION,
ZANIDATAMAB,
ZYMEWORKS INC. As a result of this development milestone, Zymeworks will receive a US$8 million payment under its zanidatamab collaboration agreement with BeiGene.
Key Points:
- As a result of this development milestone, Zymeworks will receive a US$8 million payment under its zanidatamab collaboration agreement with BeiGene.
- Zymeworks and BeiGene continue to work to expedite the opening of approximately 300 clinical trial sites across 38 countries in support of the global Phase 3 pivotal trial.
- Zymeworks collaborator, BeiGene, will oversee trial sites in Asia (excluding Japan), Australia and New Zealand, and Zymeworks will oversee trial sites in the rest of the world, including North and South America, Japan, Europe, Middle East and Africa.
- Zanidatamab is a bispecific antibody, based on Zymeworks Azymetric platform, that can simultaneously bind two non-overlapping epitopes of HER2, known as biparatopic binding.
Retrieved on:
Wednesday, December 8, 2021
Oncology,
Health,
Genetics,
Clinical Trials,
Pharmaceutical,
Biotechnology,
HER2/neu,
FC,
Engineering,
NYSE,
Corr,
Accelerated approval (FDA),
Twitter,
Trastuzumab,
Forward-looking statement,
Inc.,
CD47,
White Light Rock & Roll Review,
Patient,
DCR,
Docetaxel,
Phagocytosis,
Biliary tract,
Paclitaxel,
Fulvestrant,
Private Securities Litigation Reform Act,
Drug development,
Compte rendu,
Palbociclib,
News,
Breast cancer,
Cell,
Breakthrough therapy,
Priority review,
Zymeworks,
Head,
Epitope,
European Medicines Agency,
Trial of the century,
Capecitabine,
Breast,
Clinical trial,
FDA,
HER2,
Toxic leukoencephalopathy,
Cancer,
Orphan drug,
Conjugation,
Pharmaceutical industry,
Medical imaging,
Vaccine,
Zanidatamab,
Evorpacept,
Zymeworks Inc.,
ZANIDATAMAB,
EVORPACEPT,
ZYMEWORKS INC. The data are being presented at the San Antonio Breast Cancer Symposium (SABCS) taking place in San Antonio, Texas and virtually, December 7-10, 2021.
Key Points:
- The data are being presented at the San Antonio Breast Cancer Symposium (SABCS) taking place in San Antonio, Texas and virtually, December 7-10, 2021.
- The data presented at SABCS are from a clinical study of 24 patients with heavily pretreated HER2-positive metastatic breast cancer who received zanidatamab in combination with either vinorelbine (n=12), capecitabine (n=8), or paclitaxel (n=4).
- As we await additional data in early lines of breast cancer, these data in late-line present an additional registrational opportunity.
- We believe the data presented today demonstrate that zanidatamab and chemotherapy could be a new option for these patients.
Retrieved on:
Wednesday, December 1, 2021
Biotechnology,
Health,
Pharmaceutical,
Clinical Trials,
Oncology,
Patient,
Drug resistance,
CEO,
Technology,
Toxic leukoencephalopathy,
Private Securities Litigation Reform Act,
Forward-looking statement,
Achievement,
Neoplasm,
NYSE,
Breast,
Therapy,
Janssen,
FC,
Twitter,
Research,
Antibody,
FDA,
Compte rendu,
Engineering,
Drug development,
Zymeworks,
Breakthrough therapy,
Pharmaceutical industry,
Vaccine,
the Azymetric™ Platform,
the EFECT™ Platform,
Zymeworks Inc.,
THE AZYMETRIC™ PLATFORM,
THE EFECT™ PLATFORM,
ZYMEWORKS INC. Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that Janssen Biotech, Inc. (Janssen) dosed the first patient with JNJ-78306358, a bispecific antibody developed using Zymeworks Azymetric and EFECT therapeutic platforms.
Key Points:
- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that Janssen Biotech, Inc. (Janssen) dosed the first patient with JNJ-78306358, a bispecific antibody developed using Zymeworks Azymetric and EFECT therapeutic platforms.
- This is the second Janssen bispecific program utilizing Zymeworks proprietary technology platforms to enter the clinic this year, following the announcement in August of Janssens dosing of the first patient with JNJ-78278343.
- Zymeworks will receive a payment in connection with this milestone under Zymeworks 2017 licensing agreement with Janssen.
- Under the terms of that agreement, Zymeworks provided Janssen with a worldwide, royalty-bearing license to research, develop and commercialize up to six bispecific antibodies directed to Janssen therapeutic targets using Zymeworks Azymetric and EFECT platforms.
Retrieved on:
Friday, November 19, 2021
Biotechnology,
Health,
Pharmaceutical,
Clinical Trials,
Oncology,
Patient,
News,
HER2,
BTC,
GEA,
European Medicines Agency,
Private Securities Litigation Reform Act,
Forward-looking statement,
NYSE,
Priority review,
HER2/neu,
Clinical trial,
Biliary tract,
White Light Rock & Roll Review,
Breast,
Accelerated approval (FDA),
Breast cancer,
Twitter,
Capecitabine,
Zymeworks,
Paclitaxel,
Orphan drug,
Phagocytosis,
FDA,
CT,
Epitope,
Compte rendu,
Engineering,
Inc.,
Drug development,
Breakthrough therapy,
Pharmaceutical industry,
Medical imaging,
Language industry,
Vaccine,
Zanidatamab,
Zymeworks Inc.,
ZANIDATAMAB,
ZYMEWORKS INC. Zanidatamab in combination with chemotherapy was well tolerated, with encouraging and durable antitumor activity in heavily pretreated patients with HER2-positive breast cancer.
Key Points:
- Zanidatamab in combination with chemotherapy was well tolerated, with encouraging and durable antitumor activity in heavily pretreated patients with HER2-positive breast cancer.
- In addition, Zymeworks will present a Trial in Progress poster detailing the ongoing clinical trial evaluating zanidatamab in combination with the CD47-blocker, evorpacept (ALX148).
- Abstract highlights from May 3, 2021 data cut:
Twenty heavily pretreated HER2-positive breast cancer patients had been treated with zanidatamab in combination with standard of care chemotherapy (either vinorelbine, capecitabine, or paclitaxel).
- Title: Zanidatamab (ZW25), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) for HER2-positive breast cancer (BC): Results from a phase 1 study
The abstract is available on the SABCS conference website.
Retrieved on:
Tuesday, November 9, 2021
Biotechnology,
Pharmaceutical,
Health,
Clinical Trials,
University,
Breast,
Associate,
Private Securities Litigation Reform Act,
Inc.,
News,
CMO,
Division,
Engineering,
Dartmouth College,
Breakthrough therapy,
Compte rendu,
CEO,
Senior,
Multimedia,
Forward-looking statement,
Hematology,
University of Washington,
Twitter,
Zymeworks,
Columbia University,
NYSE,
Drug,
FDA,
Drug development,
Clinical research,
Pharmaceutical industry Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that Neil Josephson, M.D., who has been serving as the companys interim Chief Medical Officer (CMO) since May of this year, will transition to the permanent CMO position, effective November 15.
Key Points:
- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that Neil Josephson, M.D., who has been serving as the companys interim Chief Medical Officer (CMO) since May of this year, will transition to the permanent CMO position, effective November 15.
- View the full release here: https://www.businesswire.com/news/home/20211109006466/en/
Over the past six months, Neil has done an exemplary job of leading Zymeworks Medical organization and the advancement of our clinical pipeline, said Ali Tehrani, Ph.D., Zymeworks President and CEO.
- Before joining Seagen, he was an Associate Professor of Medicine in the Division of Hematology at the University of Washington.
- Zymeworks suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates.
